The efficacy of venlafaxine in the treatment of women with stress urinary incontinence

Objective To examine the efficacy of venlafaxine, which is used as an antidepressant, in the treatment of stress urinary incontinence. Materials and methods The study was designed as a placebo-controlled, double-blind and randomized clinical study. Patients in Group 1 ( n  = 20) were administered 75...

Full description

Saved in:
Bibliographic Details
Published in:Archives of gynecology and obstetrics 2009-03, Vol.279 (3), p.343-348
Main Authors: Erdinc, Ali, Gurates, Bilgin, Celik, Husnu, Polat, Aytac, Kumru, Selahattin, Simsek, Mehmet
Format: Article
Language:English
Subjects:
Adult
Antidepressants
Cyclohexanols - therapeutic use
Double-Blind Method
Endocrinology
Female
Gynecology
Human Genetics
Humans
Medicine
Medicine & Public Health
Obstetrics/Perinatology/Midwifery
Original Article
Patient Satisfaction
Placebos
Prospective Studies
Quality of Life
Serotonin Uptake Inhibitors - therapeutic use
Surveys and Questionnaires
Urinary incontinence
Urinary Incontinence, Stress - drug therapy
Urinary Incontinence, Stress - physiopathology
Venlafaxine Hydrochloride
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To examine the efficacy of venlafaxine, which is used as an antidepressant, in the treatment of stress urinary incontinence. Materials and methods The study was designed as a placebo-controlled, double-blind and randomized clinical study. Patients in Group 1 ( n  = 20) were administered 75 mg venlafaxine, those in Group 2 ( n  = 20) were administered placebo for 12 weeks. All the cases were evaluated in terms of weekly incontinence episode frequency (IEF), change in void interval (VI), the Incontinence Quality of Life (I-QOL) in weeks 0, 4, 8 and 12. Additionally, PGI-S was assessed at baseline and was followed by PGI-I evaluations in weeks 4, 8 and 12. Results Evaluations in weeks 0, 4, 8 and 12 did not show any significant difference in IEF, VI, IQOL and PGI-I values of placebo group ( p  > 0.05). However, in the patients who were administered venlafaxine declines in IEF and PGI-I values as well as the elevations in VI and IQOL scores showed significant changes parallel to the increasing follow-up period ( p  
ISSN:0932-0067
1432-0711
DOI:10.1007/s00404-008-0729-x